{"id":"https://openalex.org/W2273740586","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.3005","title":"First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.","display_name":"First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.","alternate_titles":[],"publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2273740586","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.3005","mag":"2273740586"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.3005","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.3005","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.3005","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2273740586"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072308451","display_name":"Howard A. Burris","orcid":"https://orcid.org/0000-0002-1501-2931","observed_orcids":["https://orcid.org/0000-0002-1501-2931"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Burris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031165814","display_name":"Jordi Ahnert Rodon","orcid":"https://orcid.org/0000-0001-6467-3632","observed_orcids":["https://orcid.org/0000-0001-6467-3632","https://orcid.org/0000-0003-2234-5248"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Rodon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027068634","display_name":"Shaleekha Sharma","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Sharma","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"R. S. Herbst","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. S. Herbst","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015190461","display_name":"Josep M. Tabernero","orcid":"https://orcid.org/0000-0002-2495-8139","observed_orcids":["https://orcid.org/0000-0002-2495-8139"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Tabernero","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059664827","display_name":"J. R. Infante","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. R. Infante","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042812896","display_name":"Al\u00e9cia Mol e Silva","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Silva","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061205509","display_name":"David Demanse","orcid":"https://orcid.org/0000-0003-1927-6720","observed_orcids":["https://orcid.org/0000-0003-1927-6720"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Demanse","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033143694","display_name":"Wolfgang Hackl","orcid":"https://orcid.org/0000-0002-2270-7897","observed_orcids":["https://orcid.org/0000-0002-2270-7897"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Hackl","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5004300577","display_name":"Jose M Baselga","orcid":"https://orcid.org/0000-0003-1361-4063","observed_orcids":["https://orcid.org/0000-0003-1361-4063"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Baselga","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":119,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"3005","last_page":"3005"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bez235","display_name":"BEZ235","score":0.9909999966621399},{"id":"https://openalex.org/keywords/idelalisib","display_name":"idelalisib","score":0.8820000290870667},{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.9229999780654907},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9800000190734863},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.765999972820282},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.9860000014305115},{"id":"https://openalex.org/keywords/cowden-syndrome","display_name":"Cowden syndrome","score":0.9100000262260437},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7260000109672546},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8330000042915344},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7459999918937683},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.44600000977516174},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.5979999899864197},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.4790000021457672},{"id":"https://openalex.org/keywords/bayesian-logistic-regression","display_name":"Bayesian logistic regression","score":0.6290000081062317}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9229874610900879},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5796321034431458},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5469035506248474},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.4893741011619568},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.4804506003856659},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.4728569984436035},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.46562477946281433},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.45111680030822754},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.4470489025115967},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.14296463131904602},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.3005","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.3005","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.3005","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2595334793","https://openalex.org/W2003331029","https://openalex.org/W2331243640","https://openalex.org/W1852342230","https://openalex.org/W2095592674","https://openalex.org/W2900994009","https://openalex.org/W2805565785","https://openalex.org/W2299607852","https://openalex.org/W2327161270","https://openalex.org/W2055722855"],"abstract_inverted_index":{"3005":[0],"Background:":[1],"The":[2],"PI3K":[3,30,58,206,251,303],"pathway":[4,31,59,304],"plays":[5],"a":[6,24,96,116,283,315],"major":[7],"role":[8],"in":[9,20,38,54,81,297,300],"cancer":[10,39],"cell":[11],"growth":[12],"and":[13,15,26,35,50,132,174,182,188,194,198,204,225,289,323],"survival,":[14],"is":[16,23,295],"frequently":[17],"aberrantly":[18],"hyperactivated":[19],"tumors.":[21,89],"BEZ235":[22,41,65,90,127,163,201,278,294,319],"potent":[25],"highly":[27],"selective":[28],"reversible":[29,183],"inhibitor":[32],"with":[33,83,121,162,192,259,282,302,320],"antiproliferative":[34],"apoptotic":[36],"activity":[37,53,125],"cells.":[40],"strongly":[42],"inhibited":[43],"activation":[44],"of":[45,126,145,212,231,243,249,254,267,274,318],"downstream":[46],"effectors":[47],"(e.g.":[48],"Akt)":[49],"displayed":[51],"antitumor":[52],"xenograft":[55],"models":[56],"harboring":[57],"alterations.":[60],"In":[61],"preclinical":[62],"toxicology":[63],"studies,":[64],"treatment":[66,185],"was":[67,79,91,113,128,279],"well":[68,280],"tolerated.":[69],"Methods:":[70],"This":[71],"phase":[72],"I,":[73],"multicenter,":[74],"open-label,":[75],"single-agent,":[76],"dose-escalation,":[77],"study":[78],"conducted":[80],"pts":[82,147,234,246,270,298],"histologically":[84],"confirmed,":[85],"advanced,":[86],"unresectable":[87],"solid":[88],"administered":[92],"once":[93],"daily":[94],"as":[95,208],"gelatin":[97],"capsule":[98],"either":[99],"fasted":[100],"or":[101,108,179,329,333],"fed":[102],"(10-1,100":[103],"mg)":[104],"until":[105],"unacceptable":[106],"toxicity":[107],"disease":[109,237],"progression.":[110],"Dose":[111],"escalation":[112],"guided":[114],"by":[115,130,210],"Bayesian":[117],"logistic":[118],"regression":[119],"model":[120],"overdose":[122],"control.":[123],"Anti-tumor":[124],"assessed":[129],"CT":[131],"PET.":[133],"Early":[134],"efficacy":[135,290],"data":[136,291],"are":[137],"based":[138],"on":[139,308],"central":[140],"review.":[141],"Results:":[142],"A":[143],"total":[144],"59":[146],"have":[148],"entered":[149],"the":[150,250,255],"trial":[151],"(13":[152],"breast":[153,223,264],"[22%],":[154],"10":[155],"CRC":[156],"[17%]).":[157],"There":[158],"were":[159,177,195,228],"no":[160],"DLTs":[161],"treatment.":[164],"Frequently":[165],"reported":[166],"AEs":[167],"included":[168],"nausea,":[169],"vomiting,":[170],"diarrhea,":[171],"fatigue/asthenia,":[172],"anemia,":[173],"anorexia;":[175],"they":[176],"mild":[178],"moderate,":[180],"manageable,":[181],"upon":[184],"discontinuation.":[186],"AUC":[187],"Cmax":[189],"increased":[190],"non-proportionally":[191],"dose":[193],"variable":[196],"within":[197],"among":[199],"pts.":[200],"exhibited":[202],"dose-":[203],"day-dependent":[205],"inhibition":[207],"measured":[209],"elevation":[211],"plasma":[213],"C-peptide":[214],"levels.":[215],"2":[216],"PR":[217],"(1":[218],"Cowden":[219],"syndrome":[220],"pt,":[221],"1":[222],"pt)":[224],"16":[226],"MR":[227],"observed.":[229],"14":[230,245,256],"51":[232],"evaluable":[233,269],"had":[235,263,271],"stable":[236],"\u22654":[238,261],"months;":[239],"tumors":[240],"from":[241],"6":[242],"these":[244],"carried":[247],"dysregulations":[248],"pathway.":[252],"4":[253],"(29%)":[257],"patients":[258],"SD":[260],"months":[262],"cancer.":[265],"18":[266],"35":[268],"detectable":[272],"decreases":[273],"18FDG-":[275],"uptake.":[276],"Conclusions:":[277],"tolerated":[281],"favorable":[284],"safety":[285],"profile.":[286],"Available":[287],"PD":[288],"show":[292],"that":[293],"active":[296],"(especially":[299],"those":[301],"dysregulated":[305],"tumors).":[306],"Based":[307],"PK":[309,324],"data,":[310],"future":[311],"studies":[312],"will":[313],"use":[314],"new":[316],"formulation":[317],"improved":[321],"bioavailability":[322],"properties.":[325],"Author":[326],"Disclosure":[327],"Employment":[328],"Leadership":[330],"Position":[331],"Consultant":[332],"Advisory":[334],"Role":[335],"Stock":[336],"Ownership":[337],"Honoraria":[338],"Research":[339],"Funding":[340],"Expert":[341],"Testimony":[342],"Other":[343],"Remuneration":[344],"Novartis":[345,350,351,352],"Exelixis,":[346],"Merck,":[347],"Novartis,":[348],"Roche":[349]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2273740586","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":13},{"year":2014,"cited_by_count":14},{"year":2013,"cited_by_count":18},{"year":2012,"cited_by_count":20}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
